alexa Adverse Drug Events Related to Canagliflozin: A Meta-Analysis of Randomized, Placebo-Controlled Trials
ISSN: 2167-1052

Advances in Pharmacoepidemiology and Drug Safety
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Adverse Drug Events Related to Canagliflozin: A Meta-Analysis of Randomized, Placebo-Controlled Trials

Shawaqfeh MS*, Bhinder MT, Halum AS, Harrington C, Muflih S and Do T
Nova Southeastern University, Palm Beach Gardens, Florida, United States
Corresponding Author : Shawaqfeh MS
Nova Southeastern University
Palm Beach Gardens, Florida, United States
Tel: 56-805-2243
E-mail: [email protected]
Received: December 02, 2015 Accepted: December 10, 2015 Published: December 12, 2015
Citation: Shawaqfeh MS, Bhinder MT, Halum AS, Harrington C, Muflih S, et al. (2015) Adverse Drug Events Related to Canagliflozin: A Meta-Analysis of Randomized, Placebo-Controlled Trials. Adv Pharmacoepidemiol Drug Saf 4:196. doi:10.4172/2167-1052.1000196
Copyright: © 2015 Shawaqfeh MS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed, Scholar Google
 

Abstract

Canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, was recently approved in United States for the treatment of type 2 diabetes mellitus in combination with diet and exercise. Two strengths were approved, 100 mg and 300 mg. The US label warns of a dose-dependent increase in volume depletion-related adverse reactions on the 300 mg dose. The purpose of this meta-analysis was to assess the dose response of canaglifozin on safety and tolerability outcomes.

A search was performed through MEDLINE, EMBASE, and Cochrane Library for clinical trials comparing canagliflozin with placebo or active controls. Keywords include canagliflozin, and meta-analysis. Reference lists of relevant articles were also used as sources. Two reviewers extracted data and evaluated pertinent studies. Study characteristics, safety outcomes of interest, and risk of bias were collected, verified and further analyzed. Canagliflozin was studied as monotherapy in 2 trials (n=270) and as an add-on therapy in 10 studies (n=2525). Ten of the studies were included in the analysis of selected safety outcomes. Length of intervention ranged from 12 to 52 weeks. All studies were randomized, comparative to either placebo or active controls. Canagliflozin treatment, , increased the risk of vulvovaginal mycotic infection (RR 4.11; CI 3.01-5.60; P<0.01), pollakiuria (RR 2.89, CI 1.84- 4.53), polyuria (RR 3.87; CI 1.66-9.05), hypoglycemia (RR 1.22; CI 1.10-1.35) and hypovolemia (RR 2.04; CI 1.13- 3.68). There were no significant dose responses among observed safety outcomes with the exception of genital infections (RR 4.12; CI 2.47-6.87). Additionally, the canagliflozin treatment group experienced a 24% reduction in serious adverse events when compared to controls (RR 0.76; 0.62-0.93; P<0.01).

This meta-analysis did not show a dose response effect of canaglifozin on treatment emergent adverse events in type 2 diabetics.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords